FAKTOR-OPTIONSSCHEIN - MODERNA | Market Closed - Boerse Frankfurt Warrants 15:42:21 2024-06-11 EDT | ||
| 4.72 EUR | +1.07% |
|
| Current month | -3.29% | ||
| 1 month | -23.66% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-11 | 4.71 | +0.86% |
| 24-06-10 | 4.67 | +1.97% |
| 24-06-07 | 4.58 | +2.46% |
| 24-06-06 | 4.47 | -0.89% |
| 24-06-05 | 4.51 | -5.85% |
Real-time Boerse Frankfurt Warrants
Last update June 11, 2024 at 03:42 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SF09EB |
| ISIN | DE000SF09EB7 |
| Date issued | 2021-06-09 |
| Strike | 219.8 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 9.97 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.48 € |
|---|---|
| Lowest since issue | 3.8 € |
| Spread | 0.01 € |
| Spread % | 0.21% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
148.4
USD
Average target price
143.9
USD
Spread / Average Target
-3.00%
- Stock Market
- Certificates
- Certificat
